国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2014年
18期
2811-2815
,共5页
慢性乙型肝炎%调节性T淋巴细胞%替比夫定%免疫阻断
慢性乙型肝炎%調節性T淋巴細胞%替比伕定%免疫阻斷
만성을형간염%조절성T림파세포%체비부정%면역조단
Chronic hepatitis B%CD4+CD25+ regulatory T cells%Telbivudine%Immunoglobulin block
目的 通过替比夫定对慢性HBV(Hepatitis B Virus)感染妊娠妇女外周血细胞CD4+CD25+调节性T细胞(CD4+CD25+ regulatory T cells)细胞率影响,探讨乙肝病毒宫内感染的可能作用机制.方法 选取慢性HBV感染孕妇100例,分为治疗组和对照组,治疗前及治疗后1月、3月、分娩前流式细胞术检测孕产妇Tregs比率,新生儿出生后检测乙肝五项及HBVDNA定量,酶联免疫吸附法检测乙肝五项,实时荧光定量PCR检测孕妇及新生儿HBVDNA定量,全自动生化分析仪检测孕妇肝功能.结果 对照组孕妇所生49例新生儿中,有5例HBsAg阳性,阳性率为11.2%,治疗组孕妇所生50例新生儿中有0例HBsAg阳性,阳性率为0%,两组相比差异具有统计学意义(x2=5.373,P<0.05).治疗组孕妇外周血Tregs比率治疗前、治疗后1月、3月、分娩前Tregs分别为(4.85±1.83)%、(3.26±1.39)%、(2.24±1.47)%、(1.78±0.56)%,对照组妇外周血Tregs比率治疗前、治疗后1月、3月、分娩前外周血Tregs比例分别为:(4.62±2.01)%、(4.59±2.51)%、(3.42±2.90)%、(1.99±1.64)%.妊娠时间与替比夫定抗病毒治疗之间有交互作用(F=3.88,P<0.05),治疗组与对照组CD4+CD25+调节性T细胞的差异有统计学意义(F=10.56,P<0.05).治疗前后不同时间的CD4+CD25+调节性T细胞的差异有统计学意义(F=42.39,P< 0.001).结论 替比夫定能降低乙肝母婴垂直传播,降低妊娠妇女Tregs细胞比率.
目的 通過替比伕定對慢性HBV(Hepatitis B Virus)感染妊娠婦女外週血細胞CD4+CD25+調節性T細胞(CD4+CD25+ regulatory T cells)細胞率影響,探討乙肝病毒宮內感染的可能作用機製.方法 選取慢性HBV感染孕婦100例,分為治療組和對照組,治療前及治療後1月、3月、分娩前流式細胞術檢測孕產婦Tregs比率,新生兒齣生後檢測乙肝五項及HBVDNA定量,酶聯免疫吸附法檢測乙肝五項,實時熒光定量PCR檢測孕婦及新生兒HBVDNA定量,全自動生化分析儀檢測孕婦肝功能.結果 對照組孕婦所生49例新生兒中,有5例HBsAg暘性,暘性率為11.2%,治療組孕婦所生50例新生兒中有0例HBsAg暘性,暘性率為0%,兩組相比差異具有統計學意義(x2=5.373,P<0.05).治療組孕婦外週血Tregs比率治療前、治療後1月、3月、分娩前Tregs分彆為(4.85±1.83)%、(3.26±1.39)%、(2.24±1.47)%、(1.78±0.56)%,對照組婦外週血Tregs比率治療前、治療後1月、3月、分娩前外週血Tregs比例分彆為:(4.62±2.01)%、(4.59±2.51)%、(3.42±2.90)%、(1.99±1.64)%.妊娠時間與替比伕定抗病毒治療之間有交互作用(F=3.88,P<0.05),治療組與對照組CD4+CD25+調節性T細胞的差異有統計學意義(F=10.56,P<0.05).治療前後不同時間的CD4+CD25+調節性T細胞的差異有統計學意義(F=42.39,P< 0.001).結論 替比伕定能降低乙肝母嬰垂直傳播,降低妊娠婦女Tregs細胞比率.
목적 통과체비부정대만성HBV(Hepatitis B Virus)감염임신부녀외주혈세포CD4+CD25+조절성T세포(CD4+CD25+ regulatory T cells)세포솔영향,탐토을간병독궁내감염적가능작용궤제.방법 선취만성HBV감염잉부100례,분위치료조화대조조,치료전급치료후1월、3월、분면전류식세포술검측잉산부Tregs비솔,신생인출생후검측을간오항급HBVDNA정량,매련면역흡부법검측을간오항,실시형광정량PCR검측잉부급신생인HBVDNA정량,전자동생화분석의검측잉부간공능.결과 대조조잉부소생49례신생인중,유5례HBsAg양성,양성솔위11.2%,치료조잉부소생50례신생인중유0례HBsAg양성,양성솔위0%,량조상비차이구유통계학의의(x2=5.373,P<0.05).치료조잉부외주혈Tregs비솔치료전、치료후1월、3월、분면전Tregs분별위(4.85±1.83)%、(3.26±1.39)%、(2.24±1.47)%、(1.78±0.56)%,대조조부외주혈Tregs비솔치료전、치료후1월、3월、분면전외주혈Tregs비례분별위:(4.62±2.01)%、(4.59±2.51)%、(3.42±2.90)%、(1.99±1.64)%.임신시간여체비부정항병독치료지간유교호작용(F=3.88,P<0.05),치료조여대조조CD4+CD25+조절성T세포적차이유통계학의의(F=10.56,P<0.05).치료전후불동시간적CD4+CD25+조절성T세포적차이유통계학의의(F=42.39,P< 0.001).결론 체비부정능강저을간모영수직전파,강저임신부녀Tregs세포비솔.
Objective To explore the mechanism of intrauterine Hepatitis B Virus infection observing the influence of telbivudine on CD4+CD25+ regulatory T cells in the peripheral blood of pregnant women with chronic HBV infection.Methods 100 pregnant women with chronic HPV infection were selected and divided into a treatment group,treated with telbivudine,and a control group,treated without telbivudine,50 for each group.Before and 1 and 3 months after the treatment and before delivery,the Tregs ratios were detected by flowcytometry and HBVDNA loads were detected by PCR.The 5 indicators of HBV in the infants were detected by enzyme-linked immunosorbent assay and the HBVDNA loads in the infants were detected by PCR after their birth.Results Among the 49 infants given birth by the control group,5 (11.2%) were positive in HBsAg; among the 50 infants given birth by the treatment group,none was positive in HBsAg; with a statistical difference (x 2=5.373,P < 0.05).Before and 1 and 3 months after the treatment and before delivery,the Tregs ratio was (4.85 ± 1.83) %,(3.26 ± 1.39) %,(2.24 ± 1.47) %,and (1.78 ± 0.56) % in the treatment group,respectively,and was (4.62 ± 2.01) %,(4.59 ± 2.51) %,(3.42 ± 2.90) %,and (1.99 ± 1.64) % in the control group,respectively.There was interaction between pregnant time and antivirus treatment by telbivudine(F=3.88,P < 0.05).There were statistical differences in the expression of CD4+CD25+ regulatory T cells between the 2 groups (F=10.56,P < 0.05) and between before and different times after the treatment (F=42.39,P < 0.001).Conclusion Telbivudine treatment reduce parental HBV transmission rate and decrease the Tregs ratio of pregnant women.